Glofitamab in Relapsed/Refractory Large B Cell Lymphoma – Real-World Experience in Hong Kong

Dr. Ryan CW Ho

MBBS (Hons), MRes(Med), MRCP (UK), FHKCP, FHAKM (Medicine)

Division of Haematology, Medical Oncology and HSCT

Department of Medicine, Queen Mary Hospital

Disclosures

- None

Acknowledgement

- Dr. Thomas Chan
- Prof. Eric Tse
- Prof. YL Kwong

- Roche HK – Compassionate Use Programme for Glofitamab

Introduction

- Bi-specific antibody against CD20 x CD3 for R/R DLBCL
- R/R DLBCL
- FDA-approved since June 2023



N Engl J Med. 2022 Dec 15;387(24):2220-2231.

Total Patients Analyzed

18

Study Centres

- Queen Mary Hospital
- Pamela Youde Nethersole Eastern Hospital

Data Collection Period

2021-07-30
to
2025-08-12

Follow-up Duration

13.2 months
(Median)

Range: 1 - 47.3 months

The Present Study

Demographics

Age at Treatment Start

Median: 62

50 — 87

Sex Distribution

Female: 9 (50%) Male: 9 (50%)

Hepatitis B Status

No HBV	Occult	Chronic
9 (50%)	**6** (33.3%)	**3** (16.7%)

*Note: 1 patient had detectable HBV DNA <10 IU/mL.

Disease Characteristics

83.3%
Stage III-IV

100%
Extranodal Sites

38.9%
Bulky Disease

11.1%
Bone Marrow Inv.

0%
CNS Involvement

Histology

DLBCL	15 (83.3%)
HGBL	1 (5.6%)
Transformed FL	1 (5.6%)
Transformed MALT	1 (5.6%)

Prior Therapy

Prior Lines of Therapy

Median: 5

3 — 8

Prior Treatment Exposures

Refractory to Last Line	14 (77.8%)
Prior Bendamustine	13 (72.2%)
Prior Polatuzumab	13 (72.2%)
Prior CAR-T Therapy	7 (38.9%)
Prior Autologous HSCT	3 (16.7%)

Key Characteristics of the Cohort



The HK Glofitamab Cohort in Swimmer's Plot









Response & Survival

Safety

Cytokine Release Syndrome (CRS)

38.9%

Any Grade CRS

(n=7)

Grade Breakdown

Grade 1	5 (27.8%)
Grade 2	2 (11.1%
Grade ≥3	0 (0%)

Immune Effector Cell-Associated Neurotoxicity (ICANS)

5.6%

Any Grade ICANS

(n=1)

5.6%

Grade ≥3 ICANS

(n=1)

Hematologic Toxicities

Anemia

G ≥3 | G 1-2

All Grades: **100%**

Grade ≥3: **44.4%**

Thrombocytopenia

G ≥3 | G 1-2

All Grades: **83.3%**

Grade ≥3: **38.9%**

Neutropenia

G ≥3 | G 1-2

All Grades: **72.2%**

Grade ≥3: **44.4%**

Hong Kong Data in a Global Context

Metric	Current Study (N=18)	Shumilov '25 (N=70)	Atesoglu '23 (N=43)	Gurion '25 (N=35)	Hsu '24 (N=51)
ORR (%)	55.6	46	37	34	56
CR rate (%)	44.4	27	21	14	23
Median PFS (mo)	3.6	3.6	3.3	2.0	3.2
Median OS (mo)	15.7	5.7	8.8	4.0	8.4
CRS (All Grades, %)	38.9	39	28	37	N/A*
ICANS (All Grades, %)	5.6	10	7	11	6
Prior CAR-T (%)	38.9	13	14	23	8

*Hsu 2024 reported CRS events, not percentage of patients, and is not directly comparable.

Comparing HK Data with International Reports

Conclusion

- Real world efficacy on par with international experience
- Extra-nodal disease not a barrier to response
- HBV-DNA negativity provides sufficient clearance
- One instance of severe ICANS with NCSE

Thank you!